Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation

Journal of Controlled Release

Volumn 167, Issue 1, 2013, Pages 85-91

  Nguyen, Tri Hung ^a   Tan, Angel ^b   Santos, Leilani ^a   Ngo, Devi ^a   Edwards, Glenn A ^c   Porter, Christopher J H ^a   Prestidge, Clive A ^b   Boyd, Ben J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Arthritis; Beagle; Bioavailability; Celecoxib; Nanoparticles; Silica

Indexed keywords

ADJUVANT-INDUCED ARTHRITIS; ARTHRITIS; BEAGLE; BIOAVAILABILITY; CELECOXIB; MICROPARTICLE SYSTEMS; ORAL BIOAVAILABILITIES; POORLY WATER-SOLUBLE DRUGS;

NANOPARTICLES; SILICA; TISSUE;

BIOCHEMISTRY;

CELECOXIB; NANOPARTICLE; OCTANOIN; SILICA LIPID HYBRID MICROPARTICLE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; FEMALE; HISTOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE INJURY; TREATMENT DURATION;

ANIMALS; ARTHRITIS, INFECTIOUS; BIOLOGICAL AVAILABILITY; CAPRYLATES; CYCLOOXYGENASE 2 INHIBITORS; DOGS; FEMALE; GLYCERIDES; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84874006669     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.01.012     Document Type: Article

References (36)

1. C.J.H. Porter, N. Trevaskis, and W.N. Charman Lipids and lipid-based formulations; optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
2. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
3. C. Pouton, and C. Porter Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies Adv. Drug Deliv. Rev. 60 2008 625 637
4. C.W. Pouton Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems Eur. J. Pharm. Sci. 11 2000 S93 S98
5. B. Rege, J. Kao, and J. Polli Effects of non-ionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 2002 237 246
6. K. Bogman, Y. Zysset, L. Degan, G. Hopfgartner, H. Gutmann, J. Alsenz, and J. Drewe P-glycoprotein and surfactants: effect on intestinal talinolol absorption Clin. Pharmacol. Ther. 77 2005 24 32
7. H. Zhang, M. Yao, R. Morrison, and S. Chong Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein subtrate, digoxin, in rats Arch. Pharm. Res. 26 2003 768 772
8. M. Malingre, J. Schellens, O. Tellingen, M. Ouwehand, H. Bardelmeijer, H. Rosing, F. Koopman, M. Schot, T.B. Huininik, and J. Beijnen The co-solvent cremophor EL limits absorption of orally administered paclitaxel in cancer patients Br. J. Cancer 85 2001 1472 1477
9. E. Swenson, W. Milisen, and W. Curatolo Intestinal permeability enhancement efficacy, acute local toxicity, and reversibility Pharm. Res. 11 1994 1132 1142
10. H. Bardelmeijer, M. Ouwehand, M. Malingre, J. Schellens, and O. Tellingen Entrapment by Cremophor EL decreases the absorption of pacitaxel from the gut Cancer Chemother. Pharmacol. 49 2002 119 125
11. R. Aveyard, B. Binks, and J. Clint Emulsion stabilised solely by colloidal particles Adv. Colloid Interface Sci. 100-102 2003 503 546
12. B. Midmore Preparation of a novel silica-stabilized oil/water emulsion Colloids Surf., A 132 1998 257 265
13. H. Hassander, B. Johansson, and B. Tornell The mechanism of emulsion stabilization by small silica (Ludox) particles Colloids Surf. 40 1989 93 105
14. B. Binks, and S. Lumsdon Stability of oil-in-water emulsion stabilised by silica particles Phys. Chem. Chem. Phys. 1 1999 3007 3016
15. S. Simovic, and C. Prestidge Colloidosomes from the controlled interaction of submictrometer triglyceride droplets and hydrophilic silica nanoparticles Langmuir 24 2008 7132 7137
16. S. Simovic, P. Heard, H. Hui, Y. Song, F. Peddie, A.K. Davey, A. Lewis, T. Rades, and C.A. Prestidge Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs Mol. Pharm. 6 2009 861 872
17. A. Tan, S. Simovic, A.K. Davey, T. Rades, and C.A. Prestidge Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs J. Control. Release 134 2009 62 70
18. G. Dollo, P. Le Corre, A. Guerin, F. Chevanne, J. Burgot, and R. Leverge Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs Eur. J. Pharm. Sci. 19 2003 273 280
19. I. Ahmed, M. Aboul-Einien, O. Mohamed, and S. Farid Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states Eur. J. Pharm. Sci. 35 2008 219 225
20. M. Shively, and D. Thompson Oral bioavailability of vancomycin solid-state emulsions Int. J. Pharm. 177 1995 119 122
21. L.H. Lim, A. Tan, S. Simovic, and C.A. Prestidge Silica-lipid hybrid microcapsules: influence of lipid and emulsifier type on in vitro performance Int. J. Pharm. 409 2011 297 306
22. A. Tan, S. Simovic, A.K. Davey, T. Rades, B.J. Boyd, and C.A. Prestidge Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems Mol. Pharm. 7 2010 522 532
23. A. Tan, A. Martin, T.-H. Nguyen, B.J. Boyd, and C.A. Prestidge Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption Angew. Chem. 124 2012 5571 5575
24. A. Tan, A. Davey, and C. Prestidge Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib Pharm. Res. 28 2011 2273 2287
25. A. Tan, S. Simovic, A. Davey, T. Rades, and C. Prestidge Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs J. Control. Release 134 2008 62 70
26. S. Paulson, M. Vaughn, S. Jessen, Y. Lawal, C. Gresk, B. Yan, T. Maziasz, C. Cook, and A. Karim Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption J. Pharmacol. Exp. Ther. 297 2001 638 645
27. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. Pittman, and S. Spector Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies Pharm. Res. 9 1992 588 592
28. L.L. Santos, E.F. Morand, P. Hutchinson, N.W. Boyce, and S.R. Holdsworth Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis Clin. Exp. Immunol. 107 1997 248 253
29. E. Beaulieu, D. Ngo, L. Santos, Y.H. Yang, M. Smith, C. Jorgensen, V. Escriou, D. Scherman, G. Courties, F. Apparailly, and E.F. Morand Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis Arthritis Rheum. 62 2010 2651 2661
30. K. Lentz, M. Quitko, D. Morgan, J. Grace, C. Gleason, and P. Marathe Development and validation of a preclinical food effect model J. Pharm. Sci. 96 2007 459 472
31. D. Stempak, J. Gammon, J. Halton, M. Champagne, G. Koren, and S. Baruchel Modulation of celecoxib pharmacokinetics by food in pediatric patients Clin. Pharmacol. Ther. 77 2005 226 228
32. G. Kossena, W. Charman, B. Boyd, and C. Porter Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water soluble drug J. Pharm. Sci. 94 2005 481 492
33. G.A. Kossena, W.N. Charman, B.J. Boyd, D.E. Dunstan, and C.J.H. Porter Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach J. Pharm. Sci. 93 2004 332 348
34. D.C. Monkhouse, and J.L. Lach Use of adsorbents in enhancement of drug dissolution II J. Pharm. Sci. 61 1972 1435 1441
35. C.J.H. Porter, A. Kaukonen, B.J. Boyd, G.A. Edwards, and W.N. Charman Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid based formulation Pharm. Res. 21 2004 1405 1412
36. Y. Hu, Z. Zhi, T. Wang, T. Jiang, and S. Wang Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy Eur. J. Pharm. Biopharm. 79 2011 544 551